Clarity Pharmaceuticals pioneers world first use of copper radioisotopes for diagnosis, dosimetry and treatment of cancer Sydney, Australia, 24 May 2016 – Clarity Pharmaceuticals, an emerging Australian biotech company specialising in the treatment of serious disease, has raised AU$2 million to develop its clinical pipeline using its proprietary drug targeting technology. The investment round includes…Details
At Clarity, our mission is to develop innovative radiopharmaceutical products and offer seamless preclinical to clinical imaging services that ensure better patient outcomes.
Clarity is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally. It was established in 2010 as a private, Sydney-based life sciences company.
Clarity’s platform technology allows antibodies to be radiolabeled and visualised using PET imaging. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach to therapy by only treating those patients that are likely to respond to therapy and excluding those that won’t respond to therapy. This precision medicine approach is at the forefront of drug development.